PBS Biotech Partners with Organoid COMMONS to Enhance Drug Discovery Scenarios
PBS Biotech, a prominent player in the field of advanced cell therapy, has officially joined Organoid COMMONS, an innovative consortium aimed at revolutionizing drug discovery by refining human-relevant organoid models. This partnership marks a significant step toward bridging the existing gap between academic research and industrial applications in biotechnologies.
Established with the objective of accelerating the standardization and scalability of organoid technologies, Organoid COMMONS brings together key stakeholders from the biotechnology landscape. The consortium's efforts are directed at ensuring that the New Approach Methodologies (NAMs) will be developed to provide high-quality organoid models. This, in turn, aims to reduce the dependency on traditional animal testing methods, which have long been a concern in the pharmaceutical industry.
PBS Biotech's profound bioprocess expertise, alongside its vertically integrated Vertical-Wheel® bioreactor technology, positions it uniquely in this consortium. The advanced bioreactor is designed to create uniform, low-shear hydrodynamic environments that tackle many of the industry's existing bottlenecks. By facilitating linear scalability from benchtop experiments to Good Manufacturing Practice (GMP) production, PBS Biotech plays a critical role in enhancing organoid yield, viability, and reducing batch-to-batch variability -- all pivotal concerns in drug development.
In a statement reflecting on this milestone, CEO Martin Simonetti expressed his enthusiasm about the alignment between PBS Biotech’s mission and the goals of Organoid COMMONS. He emphasized that this collaboration would enable developers to transcend manufacturing bottlenecks, thereby preserving the integrity of cell quality and function throughout the process. The common aim is to set new benchmarks that will pave the way for groundbreaking advancements in human-centric drug discovery and regenerative medicine.
The integration of PBS Biotech into Organoid COMMONS contributes to the development of a pooled knowledge base encompassing standardized procedures and scalable tools that cater to broader life sciences and pharmaceutical sectors. By ensuring seamless cooperation among biopharmaceutical innovators, PBS Biotech aims to help fast-track the transition from cutting-edge research to market-ready applications.
About PBS Biotech: PBS Biotech is dedicated to transforming the field of cell therapy manufacturing through its innovative bioreactor technologies. The company’s patented Vertical-Wheel® bioreactor offers gentle, low-shear mixing capabilities crucial for process development across clinical and commercial manufacturing stages. The company collaborates with top-tier biotechnology firms, contract development and manufacturing organizations (CDMOs), and academic entities globally, aiming to expedite the launch of transformative cell therapies.
About Organoid COMMONS: This collaborative consortium is focused on the standardization, industrialization, and democratization of organoid technologies. It creates an open framework for tool providers, therapeutic developers, and regulatory experts to work together, thereby hastening the implementation of human-relevant models in the realms of drug discovery and personalized medicine.
In conclusion, PBS Biotech’s entry into Organoid COMMONS reflects a pivotal movement in the biopharmaceutical industry, as stakeholders unite to pursue innovative solutions that can reshape the future of drug discovery and development, steering away from outdated practices and towards a more ethical and effective approach.
Established with the objective of accelerating the standardization and scalability of organoid technologies, Organoid COMMONS brings together key stakeholders from the biotechnology landscape. The consortium's efforts are directed at ensuring that the New Approach Methodologies (NAMs) will be developed to provide high-quality organoid models. This, in turn, aims to reduce the dependency on traditional animal testing methods, which have long been a concern in the pharmaceutical industry.
PBS Biotech's profound bioprocess expertise, alongside its vertically integrated Vertical-Wheel® bioreactor technology, positions it uniquely in this consortium. The advanced bioreactor is designed to create uniform, low-shear hydrodynamic environments that tackle many of the industry's existing bottlenecks. By facilitating linear scalability from benchtop experiments to Good Manufacturing Practice (GMP) production, PBS Biotech plays a critical role in enhancing organoid yield, viability, and reducing batch-to-batch variability -- all pivotal concerns in drug development.
In a statement reflecting on this milestone, CEO Martin Simonetti expressed his enthusiasm about the alignment between PBS Biotech’s mission and the goals of Organoid COMMONS. He emphasized that this collaboration would enable developers to transcend manufacturing bottlenecks, thereby preserving the integrity of cell quality and function throughout the process. The common aim is to set new benchmarks that will pave the way for groundbreaking advancements in human-centric drug discovery and regenerative medicine.
The integration of PBS Biotech into Organoid COMMONS contributes to the development of a pooled knowledge base encompassing standardized procedures and scalable tools that cater to broader life sciences and pharmaceutical sectors. By ensuring seamless cooperation among biopharmaceutical innovators, PBS Biotech aims to help fast-track the transition from cutting-edge research to market-ready applications.
About PBS Biotech: PBS Biotech is dedicated to transforming the field of cell therapy manufacturing through its innovative bioreactor technologies. The company’s patented Vertical-Wheel® bioreactor offers gentle, low-shear mixing capabilities crucial for process development across clinical and commercial manufacturing stages. The company collaborates with top-tier biotechnology firms, contract development and manufacturing organizations (CDMOs), and academic entities globally, aiming to expedite the launch of transformative cell therapies.
About Organoid COMMONS: This collaborative consortium is focused on the standardization, industrialization, and democratization of organoid technologies. It creates an open framework for tool providers, therapeutic developers, and regulatory experts to work together, thereby hastening the implementation of human-relevant models in the realms of drug discovery and personalized medicine.
In conclusion, PBS Biotech’s entry into Organoid COMMONS reflects a pivotal movement in the biopharmaceutical industry, as stakeholders unite to pursue innovative solutions that can reshape the future of drug discovery and development, steering away from outdated practices and towards a more ethical and effective approach.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.